Search Page

1

Cite

Share

Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.

Singer JW, Fleischman A, Al-Fayoumi S, Mascarenhas JO, Yu Q, Agarwal A. Singer JW, et al. Oncotarget. 2018 Sep 7;9(70):33416-33439. doi: 10.18632/oncotarget.26058. eCollection 2018 Sep 7. Oncotarget. 2018. PMID: 30279971 Free PMC article. Review.

Cite

Share

2

Cite

Share

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.

Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Mascarenhas J, et al. Among authors: singer jw. JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818. JAMA Oncol. 2018. PMID: 29522138 Free PMC article. Clinical Trial.

Cite

Share

3

Cite

Share

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.

Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN. Mesa RA, et al. Among authors: singer jw. Lancet Haematol. 2017 May;4(5):e225-e236. doi: 10.1016/S2352-3026(17)30027-3. Epub 2017 Mar 20. Lancet Haematol. 2017. PMID: 28336242 Free PMC article. Clinical Trial.

Cite

Share

4

Cite

Share

Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.

Singer JW. Singer JW. J Control Release. 2005 Dec 5;109(1-3):120-6. doi: 10.1016/j.jconrel.2005.09.033. Epub 2005 Nov 16. J Control Release. 2005. PMID: 16297482 Review.

Cite

Share

5

Cite

Share

Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.

Singer JW, Shaffer S, Baker B, Bernareggi A, Stromatt S, Nienstedt D, Besman M. Singer JW, et al. Anticancer Drugs. 2005 Mar;16(3):243-54. doi: 10.1097/00001813-200503000-00003. Anticancer Drugs. 2005. PMID: 15711176 Review.

Cite

Share

6

Cite

Share

Radiopharmaceutical reimbursement rates.

Singer JW. Singer JW. JAMA. 2008 Jun 4;299(21):2512; author reply 2512-3. doi: 10.1001/jama.299.21.2512-c. JAMA. 2008. PMID: 18523217 No abstract available.

Cite

Share

7

Cite

Share

Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate.

Chipman SD, Oldham FB, Pezzoni G, Singer JW. Chipman SD, et al. Among authors: singer jw. Int J Nanomedicine. 2006;1(4):375-83. doi: 10.2147/nano.2006.1.4.375. Int J Nanomedicine. 2006. PMID: 17722272 Free PMC article. Review.

Cite

Share

8

Cite

Share

Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data.

Singer JW, Baker B, De Vries P, Kumar A, Shaffer S, Vawter E, Bolton M, Garzone P. Singer JW, et al. Adv Exp Med Biol. 2003;519:81-99. doi: 10.1007/0-306-47932-X_6. Adv Exp Med Biol. 2003. PMID: 12675210 Review. No abstract available.

Cite

Share

9

Cite

Share

The use of recombinant human granulocyte macrophage colony-stimulating factor in autologous and allogeneic bone marrow transplantation.

Nemunaitis J, Singer JW. Nemunaitis J, et al. Among authors: singer jw. Cancer Invest. 1993;11(2):224-8. doi: 10.3109/07357909309024843. Cancer Invest. 1993. PMID: 8462023 Review.

Cite

Share

10

Cite

Share

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.

Singer JW, Al-Fayoumi S, Taylor J, Velichko S, O'Mahony A. Singer JW, et al. PLoS One. 2019 Sep 27;14(9):e0222944. doi: 10.1371/journal.pone.0222944. eCollection 2019. PLoS One. 2019. PMID: 31560729 Free PMC article.

Cite

Share